AHMEDABAD: Cadila Pharmaceuticals Ltd, an Ahmedabad-based drug maker has launched a lung cancer treatment drug - Mycidac-C.
The company claims that the drug Mycidac-C is for the first time in the world an affordable, unique and innovative drug for the treatment of lung cancer. As per the company's statement, Mycidac-C is an innovative research product for the patients suffering from Non Small Cell Lung Cancer (NSCLC). The drug has been approved for launch in India by the Drug Controller General of India (DCGI). It targets Desmocolin-3, a novel target.
Dr Rajiv I Modi, Chairman and Managing Director of Cadila Pharmaceuticals said, "We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years."
This is a first in the class active immunotherapy as well as drug targeting Desmocollin-3. It is a breakthrough in the management of squamous cell NSCLC. There has been no significant innovation in management of squamous NSCLC since the introduction of platinum containing doublet in 1983. Besides affordability and other advantages, Mycidac-C has no systemic side effects during the treatment. Mycidac-C is to be used with platinum containing doublet therapy.
As per the World Health Organisation (WHO) report, approximately 1.25 million people are diagnosed with lung cancer every year worldwide. Around 30% of them suffer from squamous NSCLC. Lung Cancer kills more people than the three next commonest cancers combined.
The company claims that the drug Mycidac-C is for the first time in the world an affordable, unique and innovative drug for the treatment of lung cancer. As per the company's statement, Mycidac-C is an innovative research product for the patients suffering from Non Small Cell Lung Cancer (NSCLC). The drug has been approved for launch in India by the Drug Controller General of India (DCGI). It targets Desmocolin-3, a novel target.
Dr Rajiv I Modi, Chairman and Managing Director of Cadila Pharmaceuticals said, "We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years."
This is a first in the class active immunotherapy as well as drug targeting Desmocollin-3. It is a breakthrough in the management of squamous cell NSCLC. There has been no significant innovation in management of squamous NSCLC since the introduction of platinum containing doublet in 1983. Besides affordability and other advantages, Mycidac-C has no systemic side effects during the treatment. Mycidac-C is to be used with platinum containing doublet therapy.
As per the World Health Organisation (WHO) report, approximately 1.25 million people are diagnosed with lung cancer every year worldwide. Around 30% of them suffer from squamous NSCLC. Lung Cancer kills more people than the three next commonest cancers combined.
No comments:
Post a Comment